MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients

K.J. Lenos; J.A.C.M. Goos; I.M. Vuist; S.H. den Uil; P.M. Delis-van Diemen; E.J.T. Belt; H.B.A.C. Stockmann; H. Bril; M. de Wit; B. Carvalho; S. Giblett; C.A. Pritchard; G.A. Meijer; Y. van Kooyk; R.J.A. Fijneman; S.J. van Vliet

doi:10.18632/oncotarget.4495

MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients

K.J. Lenos, J.A.C.M. Goos, I.M. Vuist, S.H. den Uil, P.M. Delis-van Diemen, E.J.T. Belt, H.B.A.C. Stockmann, H. Bril, M. de Wit, B. Carvalho, S. Giblett, C.A. Pritchard, G.A. Meijer, Y. van Kooyk, R.J.A. Fijneman, S.J. van Vliet

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	26278-26290
Journal	Oncotarget
Volume	6
Issue number	28
DOIs	https://doi.org/10.18632/oncotarget.4495
Publication status	Published - 2015

Access to Document

10.18632/oncotarget.4495

Cite this

Lenos, K. J., Goos, J. A. C. M., Vuist, I. M., den Uil, S. H., Delis-van Diemen, P. M., Belt, E. J. T., Stockmann, H. B. A. C., Bril, H., de Wit, M., Carvalho, B., Giblett, S., Pritchard, C. A., Meijer, G. A., van Kooyk, Y., Fijneman, R. J. A., & van Vliet, S. J. (2015). MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. Oncotarget, 6(28), 26278-26290. https://doi.org/10.18632/oncotarget.4495

Lenos, K.J. ; Goos, J.A.C.M. ; Vuist, I.M. ; den Uil, S.H. ; Delis-van Diemen, P.M. ; Belt, E.J.T. ; Stockmann, H.B.A.C. ; Bril, H. ; de Wit, M. ; Carvalho, B. ; Giblett, S. ; Pritchard, C.A. ; Meijer, G.A. ; van Kooyk, Y. ; Fijneman, R.J.A. ; van Vliet, S.J. / MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. In: Oncotarget. 2015 ; Vol. 6, No. 28. pp. 26278-26290.

@article{60fb1ef9158541818f6f54ccff190119,

title = "MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients",

author = "K.J. Lenos and J.A.C.M. Goos and I.M. Vuist and {den Uil}, S.H. and {Delis-van Diemen}, P.M. and E.J.T. Belt and H.B.A.C. Stockmann and H. Bril and {de Wit}, M. and B. Carvalho and S. Giblett and C.A. Pritchard and G.A. Meijer and {van Kooyk}, Y. and R.J.A. Fijneman and {van Vliet}, S.J.",

year = "2015",

doi = "10.18632/oncotarget.4495",

language = "Undefined/Unknown",

volume = "6",

pages = "26278--26290",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "28",

}

Lenos, KJ, Goos, JACM, Vuist, IM, den Uil, SH , Delis-van Diemen, PM, Belt, EJT, Stockmann, HBAC, Bril, H, de Wit, M, Carvalho, B, Giblett, S, Pritchard, CA, Meijer, GA, van Kooyk, Y, Fijneman, RJA & van Vliet, SJ 2015, 'MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients', Oncotarget, vol. 6, no. 28, pp. 26278-26290. https://doi.org/10.18632/oncotarget.4495

MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. / Lenos, K.J.; Goos, J.A.C.M.; Vuist, I.M.; den Uil, S.H.; Delis-van Diemen, P.M.; Belt, E.J.T.; Stockmann, H.B.A.C.; Bril, H.; de Wit, M.; Carvalho, B.; Giblett, S.; Pritchard, C.A.; Meijer, G.A.; van Kooyk, Y.; Fijneman, R.J.A.; van Vliet, S.J.

In: Oncotarget, Vol. 6, No. 28, 2015, p. 26278-26290.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients

AU - Lenos, K.J.

AU - Goos, J.A.C.M.

AU - Vuist, I.M.

AU - den Uil, S.H.

AU - Delis-van Diemen, P.M.

AU - Belt, E.J.T.

AU - Stockmann, H.B.A.C.

AU - Bril, H.

AU - de Wit, M.

AU - Carvalho, B.

AU - Giblett, S.

AU - Pritchard, C.A.

AU - Meijer, G.A.

AU - van Kooyk, Y.

AU - Fijneman, R.J.A.

AU - van Vliet, S.J.

PY - 2015

Y1 - 2015

U2 - 10.18632/oncotarget.4495

DO - 10.18632/oncotarget.4495

M3 - Article

C2 - 26172302

VL - 6

SP - 26278

EP - 26290

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 28

ER -